Drugs in clinical development for multiple sclerosis: Focusing on anti-CD20 antibodies

Expert Opinion on Investigational Drugs

Volumn 22, Issue 10, 2013, Pages 1243-1253

  Gasperini, Claudio ^a   Haggiag, Shalom ^a   Ruggieri, Serena ^b  

^a Multiple Sclerosis Center   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

B cells; Multiple sclerosis; Ocrelizumab; Ofatumumab; Rituximab

Indexed keywords

ALPHA INTERFERON A; BETA INTERFERON; BETA1A INTERFERON; FINGOLIMOD; GLATIRAMER; GYLENIA; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; RITUXIMAB; UNCLASSIFIED DRUG;

ADVERSE OUTCOME; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN RECOGNITION; ANTIINFLAMMATORY ACTIVITY; B LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FOOD AND DRUG ADMINISTRATION; HEART MUSCLE ISCHEMIA; HELPER CELL; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFECTION; INFUSION RELATED REACTION; MEMORY CELL; MULTIPLE SCLEROSIS; OPPORTUNISTIC INFECTION; PATHOGENESIS; RECURRENCE RISK; RETREATMENT; REVIEW; T LYMPHOCYTE ACTIVATION; THYROID TUMOR; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE SCLEROSIS;

EID: 84884251699     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2013.820275     Document Type: Review

References (74)

1. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin 1995;16:119-46
2. Murray TJ. Diagnosis and treatment of multiple sclerosis. BMJ 2006;332:525-7
3. Compston A, Coles A. Multiple sclerosis. Lancet 2008;372:1502-17
4. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt 1):133-46
5. Trojano M, Pellegrini F, Fuiani A, et al. New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol 2007;61(4):300-6
6. Bergamaschi R, Quaglini S, Tavazzi E, et al. Immunomodulatory therapies delay disease progression in multiple sclerosis. Mult Scler 2012; Epub ahead of print
7. Hu W, Lucchinetti CF. The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol 2009;31:439-53
8. Jagessar SA, Heijmans N, Bauer J, et al. B-cell depletion abrogates T cell-mediated demyelination in an antibody-nondependent common marmoset experimental autoimmune encephalomyelitis model. J Neuropathol Exp Neurol 2012;71(8):716-28
9. Lee-Chang C, Top I, Zéphir H, et al. Primed status of transitional B cells associated with their presence in the cerebrospinal fluid in early phases of multiple sclerosis. Clin Immunol 2011;139(1):12-20
10. Bar-Or A. The immunology of multiple sclerosis. Semin Neurol 2008;28(1):29-45
11. Miller DH, Thompson AJ, Morrissey SP, et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J Neurol Neurosurg Psychiatry 1992;55(6):450-3
12. Gallo P, Chiusole M, Sanzari M, et al. Effect of high-dose steroid therapy on T-cell subpopulations. A longitudinal study in MS patients. Acta Neurol Scand 1994;89(2):95-101
13. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebocontrolled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-61
14. Goodkin D. Interferon beta-1b. Lancet 1994;344:1057-60
15. Schwid SR, Panitch HS. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus highdose, high-frequency interferon beta-1a for relapsing multiple sclerosis. Clin Ther 2007;29:2031-48
16. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995;45:1268-76
17. Hartung HP, Gonsett R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind randomized multicenter trial. Lancet 2002;360:2018-25
18. Martinelli V, Cocco E, Capra R, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011;77:1887-95
19. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910
20. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab- associated progressive multifocal leukoencephalopathy. N Engl J Med 2012;366:1870-80
21. Kappos L, Radue E-W, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401
22. R?́o J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol 2009;5:553-60
23. Disanto G, Morahan JM, Barnett MH, et al. The evidence for a role of B cells in multiple sclerosis. Neurology 2012;78:823-32
24. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17
25. Keegan M, Konig F, McClelland R, et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005;366:579-82
26. Kowarik MC, Cepok S, Sellner J, et al. CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation 2012;9:93
27. Khademi M, Kockum I, Andersson ML, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. Mult Scler 2011;17:335-43
28. Serafini B, Rosicarelli B, Magliozzi R, et al. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol 2004;14:164-74
29. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007;130:1089-104
30. Magliozzi R, Columba-Cabezas S, Serafini B, et al. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalo-myelitis. J Neuroimmunol 2004;148:11-23
31. Villar LM, Saá daba MC, Roldan E, et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest 2005;115:187-94
32. Henderson AP, Barnett MH, Parratt JD, Prineas JW. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009;66:739-53
33. Lee-Chang C, Zephir H, Top I, et al. B-cell subsets up-regulate alpha4 integrin and accumulate in the cerebrospinal fluid in clinically isolated syndrome suggestive of multiple sclerosis onset. Neurosci Lett 2011;487:273-7
34. Brettschneider J, Tumani H, Kiechle U, et al. IgG anti-bodies against measles, rubella, and varicella zoster virus predict conversion to multiple sclerosis in clinically isolated syndrome. PLoS ONE 2009;4:e7638
35. Joseph FG, Hirst CL, Pickersgill TP, et al. CSF oligoclonal band status in-forms prognosis in multiple sclerosis: a case control study of 100 patients. J Neurol Neurosurg Psychiatry 2009;80:292-6
36. Stashenko P, Nadler LM, Hardy R, et al. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980;125:1678-85
37. Beers SA, Chan CH, French RR, et al. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010;47:107-14
38. Van Meerten T, Hagenbeek A. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma. Neth J Med 2009;67:251-9
39. Maloney DG, Liles TM, Czerwinski DK, et al. Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 1994;84:2457-66
40. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000;6:443-6
41. Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?Ann Oncol 2000;11(3):374-5
42. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-908
43. Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol 2012;142:31-7
44. Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010;74:1860-7
45. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;64:395-400
46. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88
47. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebocontrolled multicenter trial. Ann Neurol 2009;66:460-71
48. Hainsworth JD, Litchy S, Barton JH, et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21:1746-51
49. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113:4834-40
50. A Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe). Available from: http://www.clinicaltrials.gov/ ct2/show/record/NCT01212094?term=NCT01212094&rank=1 [Last access 16 June 2013]
51. Kausar F, Mustafa K, Sweis G, et al. Ocrelizu-mab: a step forward in the evolution of B-cell therapy. Expert Opin Biol Ther 2009(9(7):889-95
52. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a Phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779-87.
53. Kappos L, Calabresi P, O'Connor P, et al. Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a Phase II, randomised, multicentre trial. Presented at: 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 10-13 October 2012; Lyon, France, p. 362
54. A study of ocrelizumab in comparison with interferon beta-1a (Rebif) in patients with relapsing multiple sclerosis. Available from: http://www. clinicaltrials.gov/ct2/show/record/NCT01247324?term=NCT01247324&rank=1 [Last access 16 June 2013]
55. A study of ocrelizumab in comparison with interferon beta-1a (Rebif) in patients with relapsing multiple sclerosis. Available from: http://www. clinicaltrials.gov/ct2/show/NCT01412333?term=NCT01412333&rank=1 [Last access 16 June 2013]
56. A study of ocrelizumab in patients with primary progressive multiple sclerosis. Available from: http://www.clinicaltrials.gov/ct2/show/NCT01194570? term=NCT01194570&rank=1 [Last access 16 June 2013]
57. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal anti-body for the treatment of B-cell malignancies. J Clin Oncol 2010;28:3525-30
58. Ostergaard M, Baslund B, Rigby W, et al. Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more disease-modifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study. Arthritis Rheum 2010;62:2227-38
59. Soelberg Sorensen P, Drulovic J, Havrdova E, et al. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsing-remitting multiple sclerosis (RRMS) -24-week results of a Phase II study. Presented at: 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis; 13-16 October 2010; Gothenburg, Sweden; 2010. p. 136
60. Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR). Available from: http://www.clinicaltrials.gov/ct2/show/study/NCT01457924?term= NCT01457924&rank=1 [Last access 16 June 2013]
61. Scott TF, Frohman EM, De Seze J, et al. Therapeutics and Technology Assessment Subcommittee of American Academy of Neurology. Evidence-based guideline: clinical evaluation and treatment of transverse myelitis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2011;77(24):2128-34
62. Quan C, Yu H, Qiao J, et al. Impaired regulatory function and enhanced intrathecal activation of B cells in neuromyelitis optica: distinct from multiple sclerosis. Mult Scler 2013;19(3):289-98
63. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66(10):1485-9
64. Papeix C, Vidal JS, De Seze J, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007;13(2):256-9
65. Wingerchuk DM, Weinshenker BG. Neuromyelitis optica. Curr Treat Options Neurol 2008;10(1):55-66
66. Lennon VA, Kryzer TJ, Pittock SJ, et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005;202(4):473-7
67. Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 2011;76(15):1310-15
68. Gredler V, Mader S, Schanda K, et al. Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases. J Neurol Sci 2013;328(1-2):77-82
69. Ip VH, Lau AY, Au LW, et al. Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci 2013;324(1-2):38-9
70. Bedi GS, Brown AD, Delgado SR, et al. Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 2011;17(10):1225-30
71. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65(11):1443-8
72. Lindsey JW, Meulmester KM, Brod SA, et al. J Neurol Sci 2012;317(1-2):103-5
73. Sellner J, Boggild M, Clanet M, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;17(8):1019-32
74. Emery P, Rigby W, Tak PP, et al. Serious infections with ocrelizumab in rheumatoid arthritis: pooled results from double-blind periods of the ocrelizumab phase III RA program. [abstract]. Arthritis Rheum 2010;62(Suppl 10):41